Razelle Kurzrock/froedtert.com
Mar 31, 2025, 14:52
Razelle Kurzrock: Toll-like receptor 3 – a double-edged sword
Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, shared a post on X:
“Many immunomodulators, including TLR3 and other toll like receptors, have dual inhibitory and stimulatory functions.
They are double-edged sword!”
“Toll-like receptor 3: a double-edged sword.”
Authors: Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato and Razelle Kurzrock
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53